2009
Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors
Pavlick AC, Wu J, Roberts J, Rosenthal MA, Hamilton A, Wadler S, Farrell K, Carr M, Fry D, Murgo AJ, Oratz R, Hochster H, Liebes L, Muggia F. Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors. Cancer Chemotherapy And Pharmacology 2009, 64: 803. PMID: 19221754, PMCID: PMC3901370, DOI: 10.1007/s00280-009-0931-y.Peer-Reviewed Original ResearchConceptsPeripheral blood mononuclear cellsPhase INon-hematologic tumorsPhase II dosesPhase II doseDose-limiting toxicityResultsFifty-three patientsBlood mononuclear cellsNon-hematologic malignanciesBryostatin 1Cytotoxicity of cisplatinCisplatin 50PurposePreclinical dataObjective responseContinuous infusionMononuclear cellsTolerable dosesProtein kinase C modulatorsCisplatin effectComputerized tomographyPatientsConsistent inhibitionCisplatin cytotoxicityCisplatinMinimal toxicity
2001
RTOG 9706: initial report of a phase I/II trial of bladder-conservation employing TURB, accelerated irradiation sensitized with Cisplatin followed by adjuvant MCV chemotherapy
Hagan M, Winter K, Kaufman D, Shipley W, Heney N, Toonkel L, Jones C, Roberts J. RTOG 9706: initial report of a phase I/II trial of bladder-conservation employing TURB, accelerated irradiation sensitized with Cisplatin followed by adjuvant MCV chemotherapy. International Journal Of Radiation Oncology • Biology • Physics 2001, 51: 14. DOI: 10.1016/s0360-3016(01)01849-1.Peer-Reviewed Original Research